Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Teva
Deloitte
Chinese Patent Office
Julphar
Novartis
Baxter
US Department of Justice
Colorcon
Queensland Health

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,501,409

« Back to Dashboard

Which drugs does patent 7,501,409 protect, and when does it expire?

Patent 7,501,409 protects STENDRA and is included in one NDA.

This patent has fourteen patent family members in eleven countries.
Summary for Patent: 7,501,409
Title:Preparations for oral administration
Abstract: The present invention provides a preparation for oral administration containing a medicinal substance having cGMP-specific phosphodiesterase inhibitory activity and showing decrease of solubility in the neutral and alkaline regions, wherein an acidic substance is compounded promote the dissolution of the medicinal substance in digestive tract and thus the efficacy can be expressed at the early stage after administration, and which preparation is useful in treatment of erectile dysfunction.
Inventor(s): Murakami; Hideki (Kobe, JP), Takebe; Shoji (Takatsuki, JP)
Assignee: Mitsubishi Tanabe Pharma Corporation (Osaka-shi, JP)
Application Number:10/363,322
Patent Claim Types:
see list of patent claims
Compound; Dosage form;

Drugs Protected by US Patent 7,501,409

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-001 Apr 27, 2012 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-002 Apr 27, 2012 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Metuchen Pharms STENDRA avanafil TABLET;ORAL 202276-003 Apr 27, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,501,409

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-270061Sep 06, 2000
Japan2001-231682Jul 31, 2001
PCT Information
PCT FiledSeptember 06, 2001PCT Application Number:PCT/JP01/07718
PCT Publication Date:March 14, 2002PCT Publication Number: WO02/20058

International Patents Family Members for US Patent 7,501,409

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea 100610131 ➤ Try a Free Trial
South Korea 20030029921 ➤ Try a Free Trial
Japan 4588973 ➤ Try a Free Trial
Spain 2381862 ➤ Try a Free Trial
European Patent Office 1316316 ➤ Try a Free Trial
China 1264574 ➤ Try a Free Trial
China 1462193 ➤ Try a Free Trial
Canada 2420461 ➤ Try a Free Trial
Australia 2001284444 ➤ Try a Free Trial
Australia 8444401 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Teva
AstraZeneca
Healthtrust
Harvard Business School
Citi
Daiichi Sankyo
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot